WO2010112962A1 - Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy - Google Patents
Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy Download PDFInfo
- Publication number
- WO2010112962A1 WO2010112962A1 PCT/IB2009/005753 IB2009005753W WO2010112962A1 WO 2010112962 A1 WO2010112962 A1 WO 2010112962A1 IB 2009005753 W IB2009005753 W IB 2009005753W WO 2010112962 A1 WO2010112962 A1 WO 2010112962A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hla
- epitope
- peptide
- restricted
- cryptic
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title claims description 7
- 108010013476 HLA-A24 Antigen Proteins 0.000 title description 5
- 238000005457 optimization Methods 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 253
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 148
- 108010075704 HLA-A Antigens Proteins 0.000 claims abstract description 92
- 230000005847 immunogenicity Effects 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 36
- 108091007433 antigens Proteins 0.000 claims abstract description 28
- 102000036639 antigens Human genes 0.000 claims abstract description 28
- 239000000427 antigen Substances 0.000 claims abstract description 27
- 230000028993 immune response Effects 0.000 claims abstract description 16
- 230000001965 increasing effect Effects 0.000 claims abstract description 9
- 102000011786 HLA-A Antigens Human genes 0.000 claims abstract 16
- 229920001184 polypeptide Polymers 0.000 claims description 49
- 230000002163 immunogen Effects 0.000 claims description 45
- 229940024606 amino acid Drugs 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 238000002255 vaccination Methods 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 9
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 108010048293 HER2-neu-derived peptide (780-786) Proteins 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 76
- 235000001014 amino acid Nutrition 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 22
- 108010055196 EphA2 Receptor Proteins 0.000 description 20
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- 101150029707 ERBB2 gene Proteins 0.000 description 18
- 241000699660 Mus musculus Species 0.000 description 14
- 238000011830 transgenic mouse model Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 7
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000012737 microarray-based gene expression Methods 0.000 description 6
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102210024302 HLA-B*0702 Human genes 0.000 description 4
- 108010078301 HLA-B*07:02 antigen Proteins 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102100032368 Coiled-coil domain-containing protein 110 Human genes 0.000 description 3
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 3
- 101000868824 Homo sapiens Coiled-coil domain-containing protein 110 Proteins 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- -1 NY-Eso-1 Proteins 0.000 description 2
- 108060006580 PRAME Proteins 0.000 description 2
- 102000036673 PRAME Human genes 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 description 1
- 108010055191 EphA3 Receptor Proteins 0.000 description 1
- 108010055179 EphA4 Receptor Proteins 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010065192 HER2p63 peptide Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 1
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 description 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 description 1
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001093919 Homo sapiens SEC14-like protein 2 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000009709 cytosolic degradation Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000047279 human B2M Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108010055094 transporter associated with antigen processing (TAP) Proteins 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Definitions
- the present invention relates to the field of peptide immunotherapy.
- the invention provides novel methods and materials for efficiently treating patients having an HLA- A*2402 phenotype.
- Peptide vaccination or immunotherapy is a therapeutic approach which is currently the subject of a great number of studies in the context of the treatment of cancer.
- the principle thereof is based on immunization with peptides which reproduce T cell epitopes of tumor antigens recognized by cytotoxic T lymphocytes (CTLs) 5 which play a major role in the elimination of tumor cells.
- CTLs cytotoxic T lymphocytes
- CTLs do not recognize whole protein antigens, but peptide fragments thereof, generally comprising 8 to 10 amino acids, presented by class I major histocompatibility complex (MHC I) molecules expressed on the surface of cells.
- MHC I major histocompatibility complex
- the presentation of these peptides is the result of the antigen processing which involves three steps: cytosolic degradation of the antigen by a multienzyme complex called proteasome, translocation of the peptides derived from this degradation in the endoplasmic reticulum (ER) by the TAP transporters, association of these peptides with the MHC I molecules and exportation of the peptide/MHC I complexes to the cell surface.
- the peptide/MHC I complexes interact with the specific T cell receptor (TCR) on CTL, inducing the stimulation and amplification of these CTL, which become able to attack target cells expressing the antigen from which the peptide is derived.
- TCR T cell receptor
- peptide selection takes place, which results in a hierarchy of peptides presentation.
- Peptides that are preferentially presented by the MHC I molecules are called immunodominant, while peptides which are weakly presented are called cryptic.
- Immunodominant peptides exhibit a high affinity for the MHC I and are immunogenic while cryptic peptides exhibit a low affinity for MHC I and are non-immunogenic .
- Tumor antigens are frequently self proteins over-expressed by tumors and expressed at lower levels by normal cells and tissues.
- the immune system is unable to react against these self antigens because of the self tolerance process.
- Self-tolerance concerns mainly the immunodominant peptides (Cibotti et al., 1992; Gross et al., 2004), thus explaining the incapacity of these peptides to induce a tumor immunity.
- Cryptic peptides are much less involved in self tolerance process (Cibotti et al., 1992; Gross et al., 2004; Moudgil et aL, 1999) and can therefore induce an efficient tumor immunity, provided their immunogenicity is enhanced (Engelhorn et al., 2006; Gross et al., 2004).
- the usual strategy for enhancing the immunogenicity of cryptic peptides which are non-immunogenic because of their low MHC I affinity, consists in increasing their affinity for the MHC I molecules via amino acids substitutions.
- Peptide affinity for MHC I molecules mainly depends on the presence at well defined positions (primary anchor positions) of residues called "primary anchor residues". These residues are MHC I allele specific.
- Amino acids substitutions aiming at enhancing affinity for MHC I molecule should preserve the antigenicity of such optimized peptides. Indeed, CTL generated by optimized peptides must cross-react with the corresponding native peptides. Many teams have succeeded in enhancing immunogenicity of already immunogenic peptides by increasing their affinity for HLA-A*0201 (Bakker et al., 1997; Parkhurst et al., 1996; Valmori et al., 1998).
- HLA-A* 0201 restricted cryptic peptides The inventors have previously described a general strategy to enhance affinity and immunogenicity of HLA-A* 0201 restricted cryptic peptides (Scardino et al., 2002; Tourdot and Gould, 2002) and HLA-B*0702 (WO 2008/010098).
- HLA-A*2402 is a frequently expressed molecule (27% of the population) and is one of the most common alleles in Japanese and Asian people. Identification and optimization of HLA-A* 2402 restricted tumor cryptic peptides is therefore necessary for developing efficient cancer vaccines for HLA-A* 2402 expressing patients. Several tumor immunogenic peptides presented by HLA-A* 2402 have been described to date (table 1). Antigen Sequence SEQ ID No:
- the inventors have now found a strategy to identify, in an antigen, cryptic peptides presented by HLA-A*2402 molecule, and to optimize their immunogenicity, preserving the cross-reactivity with the corresponding native cryptic peptides.
- a first aspect of the present invention is a method for identifying an HLA-A*2402-restricted cryptic epitope in an antigen, comprising a step of selecting, in said antigen, a peptide of 8 to 12 amino acids having a tyrosine (Y) in primary anchor position 2, with the proviso that the peptide does not have, simultaneously, a positively charged amino acid (arginine (R) or lysine (K)) in position 1 and a leucine (L), or a phenylalanine (F) or an isoleucine (I) in C-terminal position.
- the obtained sequences are those of putative cryptic epitopes.
- the method for identifying a HLA-A *2402-restricted cryptic epitope in an antigen further comprises step consisting in testing the immunogenicity of each putative cryptic epitope of SEQ ID No: 20, in an appropriate model, and selecting those which are non-immunogenic.
- an appropriate model is a model which predicts the immunogenicity of the peptide in an individual who expresses HLA-A*2402.
- An example of such an appropriate model is described in the experimental part and consists of HLA-A*2402 transgenic mice.
- “native peptide” will be used to designate any peptide of SEQ ID No: 20, whether its non- immunogenicity has been checked or not.
- the phrase “putative HLA- A*2402-restricted cryptic epitope” will be used to express the fact that the immunogenicity of the peptide has not been tested, and the phrase “confirmed HLA-A*2402 -restricted cryptic epitope” will be used for peptides which have been tested and have proved to be non-immunogenic in an appropriate model.
- peptide designates not only molecules in which amino acid residues (in L or D configurations) are joined by peptide (-CO-NH-) linkages, but also synthetic pseudopeptides or peptidomimetics in which the peptide bond is modified, especially to become more resistant to proteolysis, and provided their immunogenicity is not impaired by this modification.
- the selected peptide has 9 to 11 amino acids, more preferably 9 or 10 amino acids and one or more unfavourable amino acids at secondary anchor positions, for example a P (proline) in position 1 and/or a D or E or G or H or P or Q or R or K (glutamic or aspartic acid, glycine, histidine, proline, glutamine, arginine or lysine) at C-terminal position.
- P proline
- D or E or G or H or P or Q or R or K glutmic or aspartic acid, glycine, histidine, proline, glutamine, arginine or lysine
- a second aspect of the present invention is a method for increasing the immunogenicity of a HLA-A*2402-restricted cryptic epitope, comprising a step of substituting the N-terminal residue of said epitope with a positively charged amino acid (R or K), and/or substituting the C-terminal residue of said epitope with an L, F or I.
- R or K positively charged amino acid
- the C-terminal modification is the substitution by an L.
- the peptide can be produced by artificial peptide synthesis or by recombinant expression.
- the immunogenicity of a HLA-A*2402-restricted cryptic epitope in which the two first residues are RY or KY can be increased by replacing its last amino-acid by an L 5 F or I, preferentially by an L (or by adding a L, I or F at its C- terminus, provided it is not longer than 11 amino acids).
- sequence .of the selected HLA-A*2402-restricted cryptic epitope is XiYX 2 X 3 X 4 X 5 X 6 X 7 XsXeXiOL (SEQ ID No: 21), wherein Xi is any amino acid but R or K, X 2 to X 6 are any amino acid, and X 7 to X] o are any amino acid or none, the substitution of Xi by R or K is sufficient to increase its immunogenicity.
- the sequence of the selected HLA-A*2402- restricted cryptic epitope is Xi YX 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 XiOXi i (SEQ ID No: 22), wherein Xi is any amino acid but R or K, X 2 to X 6 are any amino acid, and X 7 to Xi 0 are any amino acid or none, and Xn is not an unfavourable amino acids (D or E or G or H or P or Q or R or K ), the substitution of Xi by R or K can be sufficient to increase its immunogenicity.
- the expression "optimized peptide” or “optimized immunogenic A*2402-restricted epitope” will designate an immunogenic peptide derived from a HLA-A*2402-restricted cryptic epitope (called its "cognate native peptide") by the above method.
- the optimized peptide can trigger an immune response which cross-recognizes its cognate native peptide.
- Another aspect of the present invention is hence a method for obtaining a HLA-A*2402-restricted epitope able to trigger an immune response against a HLA-A*2402-restricted cryptic epitope of an antigen, comprising the steps of (i) identifying, in said antigen, one or several native putative HLA-
- A*2402-restricted cryptic epitopes by the method according to claim 1 ;
- step (ii) testing the immunogenicity of each native epitope selected in step (i), in an appropriate model, and selecting those which are non-immuno genie;
- step (iii) for each native epitope selected in step (ii), obtaining an optimized epitope by increasing its immunogenicity, by the method as above-described;
- step (iv) testing the immunogenicity of each optimized epitope obtained in step (iii), in an appropriate model, and selecting those which are immunogenic;
- step (v) for each epitope selected in step (iv), testing if the CTLs generated against the optimized epitope also recognize its cognate native epitope, and selecting those for which the test is positive.
- step (v) the appropriate models which can be used in steps (ii) and (iv) are as described above.
- step (v) the cross-recognition can be performed by any method known by the skilled artisan, for example as described in the experimental part.
- the inventors have identified in different tumor associated antigens (hTERT, EphA2, MAGE or Her2/neu), a number of putative HLA-A*2402-restricted cryptic epitopes. When testing the immunogenicity of these epitopes, one of them proved to be immunogenic.
- the inventors have selected the peptides disclosed in Table 2 below, which are confirmed HLA-A*2402-restricted cryptic epitopes. The peptides are part of the present invention.
- Her2/neu 300 PYNYLSTDV ID N°9 Table 2 Selected confirmed cryptic HLA-A*2402 restricted peptides
- the present invention also pertains to optimized peptides derived from the cryptic peptides of SEQ ID Nos: 1 to 9, by a method according to the invention.
- Preferred examples of optimized peptides are KYGVLLKTL (SEQ ID No: 11), RYMRQFVAL (SEQ ID No: 12), RYVSRLLGI (SEQ ID No: 13), RYGKGWDLL (SEQ ID No: 14), RYLVQVQAL (SEQ ID No: 15), RYWELSNHL (SEQ ID No: 16).
- SEQ ID No: 13 and SEQ ID No: 15 have been derived from the cryptic HLA-A*2402-restricted epitopes of SEQ ID NOs: 3 and 5, respectively, by substitution of their N-terminal amino-acid with a R.
- the peptides of SEQ ID Nos: 11, 12, 14 and 16 have been derived from the peptides of SEQ ID Nos: 1, 2, 4 and 6, respectively, by substituting their N-terminal amino-acid with an R or a K and their C-terminal amino-acid with a L.
- Polyspecific tumor vaccination offers a broader control of tumor cells than monospecific vaccination, thereby reducing the risk of emergence of immune escape variants.
- Vx-006 is able to induce a polyspecific CD8 cell response both in vivo in HLA-A* 0201 transgenic HHD mice and in vitro in humans, whereas the mixture of TERT 988 Y, HER-2/neu 40 2 ⁇ and MAGE-A 24 8V9 peptides failed to induce a trispecific response.
- a chimeric polypeptide comprising several epitopes can be more efficient than a mere mixture of the same epitopes to trigger a response against more than one epitope.
- a chimeric polypeptide comprising a repetition of one single epitope can also trigger a stronger response against said epitope than a peptide consisting of said epitope.
- a polypeptide organization (either with several different epitopes or with a repetition of one single epitope) can produce new junctional epitopes, especially CD4 restricted epitopes, able to optimize the targeted peptide(s)-specific immune response.
- peptides bind directly to MHC molecules of every cells present at the site of injection.
- APC Antigenic Presenting Cells
- a further aspect of the invention is hence a chimeric polypeptide, comprising one, two, three or more HLA-A*2402-restricted cryptic epitopes or one, two, three or more optimized immunogenic HLA-A*2402-restricted epitopes as described above.
- the epitopes can be different from each other, and/or the same epitope can be repeated several times.
- HLA-A*2402- restricted cryptic or optimized immunogenic epitopes described above can hence be advantageously associated to previously described HLA-A* 0201 (WO 02/02716) and/or HLA-B*0702 peptides (WO 2008/010010 and WO 2008/010098), or to immunogenic epitopes derived from previously described tumor associated antigens, comprising CEA, PRAME, Tyrosinase, TRAG-3, NY-Eso-1, P53, Muc-1, PSA/PSMA, survivin, Melan- A/MART-1, TRP-I, TRP-2, WTl, EphAl, EphA2, EphA3, EphA4, G250/MN/CAIX, STEAP, alphafoetoprotein, RAGE-I, PAGE-I.
- a polyallelic peptides mix comprising at least a peptide according to the present invention and one different HLA- restricted epitope (HLA-A*0201, HLA-A*2402, HLA-B*0702 or others), is also part of the present invention.
- cryptic epitopes which can advantageously be combined to HLA-A*2402-restricted cryptic epitopes (either in a mix or in a chimeric polypeptide), as well as examples of optimized immunogenic epitopes which can advantageously be combined to optimized immunogenic HLA-A*2402-restricted epitopes, are described in Table 3 below. Of course, these lists are not limitative.
- Table 3 epitopes which can be combined to HLA-A*2402-restricted epitopes in chimeric polypeptides according to the invention
- polypeptide can be obtained by chemical synthesis, or by using the technology of genetic engineering (Velders et al., 2001).
- Another object of the present invention is an isolated nucleic acid molecule designed to cause the expression of a cryptic HLA- A*2402 -restricted epitope, or of an optimized immunogenic HLA-A*2402-restricted epitope, or of a chimeric polypeptide as above-described.
- designed to cause the expression of a peptide is herein meant that said peptide is expressed as such, isolated from the whole antigen from which its sequence has been selected (and, in appropriate cases, optimized as above- described), when the nucleic acid is introduced in an appropriate cell.
- the region encoding the epitope or chimeric polypeptide will typically be situated in the polynucleotide under control of a suitable promoter.
- Bacterial promoters will be preferred for expression in bacteria, which can produce the polypeptide either in vitro, or, in particular circumstances, in vivo.
- a nucleic acid according to the invention can be administered directly, using an appropriate vector.
- a tissue-specific, a strong constitutive, or an endogenous promoter can be used to control the peptide expression.
- Suitable vector systems include naked DNA plasmids, liposomal compositions to enhance delivery, and viral vectors that cause transient expression.
- viral vectors are adenovirus or vaccinia virus vectors and vectors of the herpes family, especially in a non-replicative form.
- the present invention also pertains to a pharmaceutical composition
- a pharmaceutical composition comprising at least, as an active principle, an HLA-A*2402-restricted cryptic epitope as above-described, or an optimized immunogenic epitope polypeptide as mentioned above, or a chimeric polypeptide according to the invention, or a nucleic acid encoding any of these, and/or a vector carrying said nucleic acid.
- Formulation of pharmaceutical compositions will accord with contemporary standards and techniques. Medicines intended for human administration will be prepared in adequately sterile conditions, in which the active ingredient(s) are combined with an isotonic solution or other pharmaceutical carrier appropriate for the recommended therapeutic use. Suitable formulations and techniques are generally described in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co, Easton PA).
- a HLA-A*2402-restricted epitope or a chimeric polypeptide or a nucleic acid according to the invention can be used for the preparation of a composition for preventive or curative immunotherapy, especially, for antiviral or anticancer immunotherapy.
- a pharmaceutical composition according to the invention is a vaccine.
- the components described above can be combined with an adjuvant to potentiate the immune response.
- Classic adjuvants include oil emulsions, like Incomplete Freund's Adjuvant or Montanide, and adherent surfaces such as alum.
- Adjuvants that recruit and activate dendritic cells particularly via TLR (such as bacterial DNA or bacterial membrane derived proteins) or help elicit cytotoxic T cells are especially useful.
- Other factors that otherwise boost the immune response or promote apoptosis or elimination of cancer cells can also be included in the composition, such as IL-2 or IL- 12 cytokines or GM-CSF.
- kits of parts described below can be accompanied with written instructions regarding the use of the composition or combination for eliciting an immune response and/or for the treatment of cancer.
- WO 2006/120038 the Applicant has described a vaccination protocol which enables the initiation and maintenance of a T cell response targeting sub-dominant/cryptic epitopes.
- the results reported in WO 2006/120038 demonstrate that injection of a native peptide corresponding to a sub- dominant/cryptic epitope, following vaccination with its cognate optimized peptide, can maintain the immune response initiated by said optimized peptide.
- a HLA-A* 2402-restricted cryptic epitope can hence be used for the preparation of a medicinal composition for maintaining the CTL immune response initiated by its cognate optimized peptide.
- An immunogenic peptide having an optimized immunogenic HLA-A*2402-restricted epitope sequence derived from a HLA-A*2402-restricted cryptic epitope can also be used, for the preparation of a medicinal composition for initiating a CTL immune response against said HLA-A*2402- restricted cryptic epitope.
- the present invention also encompasses a method for vaccinating a patient against a tumoral or viral antigen, wherein said method comprises a first step of vaccination with an optimized immunogenic peptide cognate to a native HLA- A*2402-restricted cryptic epitope of said antigen, followed by a second step of vaccination with said native peptide.
- the first step and/or the second step can be performed by using a chimeric polypeptide comprising one, two, three or more optimized or cryptic peptides as above-described, instead of single-epitope peptides.
- the invention also pertains to a kit of parts comprising, in separate formulations or containers (vials, tubes, etc.):
- peptides which can be part of a kit according to the invention are the peptides of SEQ ID NOs: 1 to 6, which can constitute the first peptide, the second peptide being then derived from said first peptide by a method for increasing its immunogenicity, as described above.
- kits according to the invention can hence comprise peptides of SEQ ID Nos: 1 and 11 (in separate containers), or peptides of SEQ ID Nos: 2 and 12 (in separate containers), or peptides of SEQ ID Nos: 3 and 13 (in separate containers), or peptides of SEQ ID Nos: 4 and 14 (in separate containers), or peptides of SEQ ID Nos: 5 and 15 (in separate containers), or peptides of SEQ ID Nos: 6 and 16 (in separate containers).
- kits of parts according to the invention comprise at least one chimeric polypeptide.
- the kit also comprises at least a peptide cognate to one of the epitopes comprised in the chimeric polypeptide, wherein said cognate peptide is either isolated or included in another chimeric polypeptide.
- the kit comprises, in separate formulations, a first chimeric polypeptide comprising one, two, three or more HLA-A*2402 -restricted cryptic epitopes, and a second chimeric polypeptide corresponding to its cognate HLA-A*2402-restricted immunogenic chimeric polypeptide (which means that it comprises optimized HLA-A*2402-restricted immunogenic epitopes cognate to the cryptic epitopes comprised in the first chimeric polypeptide).
- the kit comprises one, two, three or more peptides corresponding to distinct HLA-A*2402-restricted cryptic epitopes, wherein said peptides are either mixed in one single formulation, or separated in several formulations and, in a separate formulation, a chimeric polypeptide comprising the optimized HLA-A* 2402- restricted immunogenic epitopes cognate to said cryptic peptides.
- kits according to the invention comprise, in separate containers:
- a polyallelic peptides mix or a polyallelic chimeric polypeptide comprising at least a HLA-A*2402-restricted cryptic epitope as described above and at least one different HLA-restricted cryptic epitope, and
- a polyallelic peptides mix or a polyallelic chimeric polypeptide comprising at least a HLA-A*2402 -restricted immunogenic epitope cognate to the HLA- A*2402-restricted cryptic epitope recited in (i), and at least another immunogenic epitope cognate to the other cryptic epitope recited in (i).
- kits according to the invention can comprise, instead of at least part the peptides or chimeric polypeptides, nucleic acid(s) encoding said peptides or chimeric polypeptides.
- nucleic acid(s) is(are) as above-described.
- kits According to the invention, mention will be made only of the peptides (native or optimized) included therein; it is understood that chimeric polypeptide(s) (comprising native cryptic epitopes or optimized epitopes) can be enclosed in the kits instead of single-epitope peptides, and that nucleic acid(s) can also be included in addition or instead of at least part of said peptides or chimeric polypeptides.
- the kit is a vaccination kit, wherein said first (native) and second (cognate optimized) peptides are in separate vaccination doses.
- the vaccination kit comprises 2 or 3 doses of optimized peptide, and 3, 4, 5 or 6 doses of native peptide.
- a particular vaccination kit according to the invention is adapted for the first vaccination sequence of 6 injections, and comprises 2 or 3 doses of optimized peptide, and 4 or 3 doses of native peptide.
- kits comprising at least 2 doses, and up to 40 or 50 doses of native peptide, are also part of the present invention.
- the vaccination kit can comprise 2 to 3 doses of optimized peptide, and 3 to 40 or up to 50 doses of native peptide.
- said native and optimized peptides present in the kit are as described above.
- each dose comprises between 0.1 and 10 mg of peptide, preferably from 1 to 5 mg, or between 1 and 20 mg of polypeptide.
- each dose is formulated for subcutaneous injection.
- each dose can be formulated in 0.3 to 1.5 ml of an emulsion of aqueous solution emulsified with Montanide ISA51, used as an adjuvant.
- Montanide ISA51 used as an adjuvant.
- the doses are in the form of an aqueous solution.
- the doses can be in the form of a lyophilized peptide, for extemporaneous preparation of the liquid solution to be injected.
- Other possible components of said kits are one or several adjuvants, to be added to the peptide compositions before administration, and a notice describing how to use said kits.
- FIG. 2 Immunogenicity of HLA-A*2402 restricted optimized cryptic peptides.
- transgenic mice used in the described experiments were obtained by crossing HLA-A24 transgenic mice previously described (Barra et al., 1993) and H2 Kb " H2Db " knock out mice, transgenic for both human ⁇ 2 microglobulin and CD8 ⁇ chain (Perarnau et al., 1999).
- Peptides were synthesized by Epytop (N ⁇ mes, France).
- HLA-A*2402 transfected human TAP negative T2-A24 cells were previously described (Miyahara et al., 2005), and were provided by Dr. Lemonnier (Institut Pasteur, Paris, France). AU cell lines were grown in FCS 10% supplemented RPMIl 640 culture medium.
- mice were injected subcutaneously with 100 ⁇ g of peptide emulsified in Incomplete Freund's Adjuvant (IFA) in the presence of 150 ⁇ g of the I-A b restricted HBVcore ⁇ s T helper epitope (TPPAYRPPNAPIL, SEQ ID NO: 112). After 15 days, 5x10 7 spleen cells were stimulated twice in vitro with peptide (10 ⁇ M), at 6 days interval. On day 13 of culture, the bulk responder populations were tested for specific cytotoxicity against target cells expressing HLA-A*2402 and loaded with the same peptide. Cross-recognition assay.
- IFA Incomplete Freund's Adjuvant
- mice were injected subcutaneously with 100 ⁇ g of optimized peptide emulsified in Incomplete Freund's Adjuvant (IFA) in the presence of 150 ⁇ g of the I-A b restricted HBVcore 128 T helper epitope (TPPAYRPPNAPIL, SEQ ID NO: 112).
- IFA Incomplete Freund's Adjuvant
- TPPAYRPPNAPIL I-A b restricted HBVcore 128 T helper epitope
- 5x10 7 spleen cells were stimulated firstly in vitro with the optimized peptide (10 ⁇ M), and secondly on day 6 of culture with the corresponding native peptide.
- the bulk responder populations were tested for specific cytotoxicity against targets cells expressing HLA-A*2402 and loaded with the optimized, the native or an irrelevant peptide. Cytotoxic assay.
- the inventors have selected 10 native peptides according to the selection method described above. First, seven peptides were tested for their capacity to bind HLA- A*2402 molecules. All but two peptides were not or weakly able to bind to the HLA- A*2402.
- HLA- A24 transgenic mice were then vaccinated with the selected peptides, and fifteen days later, their spleen cells were in vitro stimulated twice at 6 days intervals with the peptide.
- Peptide-specific CTLs were detected in mice vaccinated with control high affinity peptides selected as having primary Y2 and/or C-terminal anchor motifs (data not shown).
- Native peptides, which were not able to bind to the HLA-A*2402 were shown to be also non immunogenic (figure 1) and Her2/neu 802, which binds to the HLA-A*2402, was shown to be immunogenic in transgenic mice. This confirms that there is a correlation between binding affinity and immunogenicity for the HLA-A*2402 restricted peptides.
- Her2/neu 802 PYGCLLDHV ++ 10 Table 5: HLA-A*2402 immunogenicity of selected cryptic peptides. (-) means that none of the mice vaccinated with the corresponding native peptides develops a specific immune response, (+) that less to 50% of vaccinated mice responded, (++) that more that 50% responded. ND: not determined
- L leucine
- Table 6 Tumor and HIV derived HLA-A*2402 restricted epitopes Optimized peptides were tested for their immunogenicity (table 7, figure 2), showing that the chosen modification enhances the capacity to induce specific immune response in HLA-A24 transgenic mice for six native peptides.
- CTLs generated in mice vaccinated with optimized peptides recognized target cells loaded with the corresponding native peptide (figure 2).
- the inventors describe a method to optimize immunogenicity of HLA-A*2402 restricted cryptic peptides. It consists of a) selecting cryptic peptides with Y2 and unfavourable amino acids in secondary anchor position 1 and/or 9; and b) substituting the unfavourable amino acids at the N-terminal position with a positively charged amino acid (R or K) and the C-terminal residue with a L when this later substitution is necessary.
- Bennaceur-Griscelli A., Faure, O., criz, P., Firat, H., Chouaib, S., Lemonnier, F.A., Davoust, J., Miconnet, I., Vonderheide, R.H. and Kosmatopoulos, K. (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest,
- Kitano, S., Okumura, S. Takemitsu, T., Yuta, A., Majima, Y., Lemonnier, F.A., Boon, T. and Shiku, H. (2005) Determination of cellularly processed HLA-A2402-restricted novel
- H2Kb, H2Db and double H2KbDb knockout mice peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses. Eur J Immunol, 29, 1243- 1252.
- Velders M.P., Weijzen, S., Eiben, G.L., Elmishad, A.G., Kloetzel, P.M., Higgins, T., Ciccarelli, R.B., Evans, M., Man, S., Smith, L. and Kast, W.M. (2001) Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol, 166, 5366-5373.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0924827A BRPI0924827A2 (en) | 2009-04-02 | 2009-04-02 | identification, optimization and use of hla-a24 cryptic epitopes for immunotherapy |
CA2756238A CA2756238A1 (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
PCT/IB2009/005753 WO2010112962A1 (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
US13/258,227 US8900600B2 (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy |
PT97859268T PT2413956T (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
HUE09785926A HUE030195T2 (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
DK09785926.8T DK2413956T3 (en) | 2009-04-02 | 2009-04-02 | IDENTIFICATION, OPTIMIZATION AND USE OF cryptic HLA-A24-EPITOPES FOR IMMUNOTHERAPY |
CN200980158591.2A CN102387813B (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and the purposes of hidden HLA-A24 epitopes for immunization therapy |
ES09785926.8T ES2608715T3 (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy |
EP09785926.8A EP2413956B1 (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
JP2012502822A JP5756792B2 (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of potential HLA-A24 epitopes for immunotherapy |
PL09785926T PL2413956T3 (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
HRP20161710TT HRP20161710T1 (en) | 2009-04-02 | 2016-12-13 | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2009/005753 WO2010112962A1 (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010112962A1 true WO2010112962A1 (en) | 2010-10-07 |
Family
ID=41381983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/005753 WO2010112962A1 (en) | 2009-04-02 | 2009-04-02 | Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy |
Country Status (13)
Country | Link |
---|---|
US (1) | US8900600B2 (en) |
EP (1) | EP2413956B1 (en) |
JP (1) | JP5756792B2 (en) |
CN (1) | CN102387813B (en) |
BR (1) | BRPI0924827A2 (en) |
CA (1) | CA2756238A1 (en) |
DK (1) | DK2413956T3 (en) |
ES (1) | ES2608715T3 (en) |
HR (1) | HRP20161710T1 (en) |
HU (1) | HUE030195T2 (en) |
PL (1) | PL2413956T3 (en) |
PT (1) | PT2413956T (en) |
WO (1) | WO2010112962A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2886127A1 (en) * | 2013-12-18 | 2015-06-24 | Vaxon Biotech | Method for emulsifying a triepitope peptide with montanide and kits for performing the same |
WO2020178744A1 (en) * | 2019-03-04 | 2020-09-10 | University Health Network | T cell receptors and methods of use thereof |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117815373A (en) * | 2013-04-07 | 2024-04-05 | 博德研究所 | Compositions and methods for personalizing neoplasia vaccines |
EP3412304A3 (en) * | 2013-10-23 | 2019-03-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
KR20230076867A (en) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | Combination therapy with neoantigen vaccine |
EP2977059A1 (en) * | 2014-07-22 | 2016-01-27 | Vaxon Biotech | Immunogenic polypeptide composed of HLA-B7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
RU2733754C2 (en) | 2015-05-20 | 2020-10-06 | Те Брод Инститьют Инк. | Common neoantigens |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
CN111363026B (en) * | 2020-03-31 | 2022-03-25 | 浙江省中医院、浙江中医药大学附属第一医院(浙江省东方医院) | Method for enhancing affinity and stability of antigen polypeptide |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
WO2024138753A1 (en) * | 2022-12-30 | 2024-07-04 | 深圳吉诺因生物科技有限公司 | Hla-a*24:02 restrictive antigen site replacement method, obtained polypeptide, and use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050386A2 (en) * | 1998-03-31 | 1999-10-07 | Geron Corporation | Human telomerase catayltic subunit variants |
EP1462456A1 (en) * | 2001-12-10 | 2004-09-29 | Kyogo Itoh | Tumor antigens |
EP1715042A1 (en) * | 2004-01-20 | 2006-10-25 | Aichi Prefecture | EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRCITED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME |
WO2007094924A2 (en) * | 2006-01-19 | 2007-08-23 | The Regents Of The University Of California | Human telomerase reverse transcriptase peptides |
WO2008010010A1 (en) * | 2006-07-12 | 2008-01-24 | Vaxon Biotech | Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE536187T1 (en) * | 2000-10-19 | 2011-12-15 | Epimmune Inc | HLA CLASS I AND CLASS II BINDING PEPTIDES AND USES THEREOF |
JP4624377B2 (en) * | 2001-12-10 | 2011-02-02 | 株式会社グリーンペプタイド | Tumor antigen |
CA2481462A1 (en) * | 2002-04-05 | 2003-10-23 | Epimmune Inc. | Heteroclitic analogs and related methods |
-
2009
- 2009-04-02 PT PT97859268T patent/PT2413956T/en unknown
- 2009-04-02 ES ES09785926.8T patent/ES2608715T3/en active Active
- 2009-04-02 EP EP09785926.8A patent/EP2413956B1/en active Active
- 2009-04-02 CN CN200980158591.2A patent/CN102387813B/en active Active
- 2009-04-02 PL PL09785926T patent/PL2413956T3/en unknown
- 2009-04-02 HU HUE09785926A patent/HUE030195T2/en unknown
- 2009-04-02 WO PCT/IB2009/005753 patent/WO2010112962A1/en active Application Filing
- 2009-04-02 BR BRPI0924827A patent/BRPI0924827A2/en not_active Application Discontinuation
- 2009-04-02 DK DK09785926.8T patent/DK2413956T3/en active
- 2009-04-02 JP JP2012502822A patent/JP5756792B2/en active Active
- 2009-04-02 CA CA2756238A patent/CA2756238A1/en not_active Abandoned
- 2009-04-02 US US13/258,227 patent/US8900600B2/en active Active
-
2016
- 2016-12-13 HR HRP20161710TT patent/HRP20161710T1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050386A2 (en) * | 1998-03-31 | 1999-10-07 | Geron Corporation | Human telomerase catayltic subunit variants |
EP1462456A1 (en) * | 2001-12-10 | 2004-09-29 | Kyogo Itoh | Tumor antigens |
EP1715042A1 (en) * | 2004-01-20 | 2006-10-25 | Aichi Prefecture | EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRCITED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME |
WO2007094924A2 (en) * | 2006-01-19 | 2007-08-23 | The Regents Of The University Of California | Human telomerase reverse transcriptase peptides |
WO2008010010A1 (en) * | 2006-07-12 | 2008-01-24 | Vaxon Biotech | Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy |
Non-Patent Citations (3)
Title |
---|
MAIER R ET AL: "PEPTIDE MOTIFS OF HLA-A3, -A24, AND -B7 MOLECULES AS DETERMINED BY POOL SEQUENCING", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 40, no. 4, 1 January 1994 (1994-01-01), pages 306 - 308, XP000995826, ISSN: 0093-7711 * |
MORISHIMA SATOKO ET AL: "Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 1 FEB 2007, vol. 120, no. 3, 1 February 2007 (2007-02-01), pages 594 - 604, XP002560331, ISSN: 0020-7136 * |
YAO A ET AL: "Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+prostate cancer patients", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, LONDON, GB, vol. 91, no. 2, 1 January 2004 (2004-01-01), pages 287 - 296, XP002990847, ISSN: 0007-0920 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2886127A1 (en) * | 2013-12-18 | 2015-06-24 | Vaxon Biotech | Method for emulsifying a triepitope peptide with montanide and kits for performing the same |
WO2015092746A1 (en) * | 2013-12-18 | 2015-06-25 | Vaxon Biotech | Method for emulsifying a triepitope peptide with montanide and kits for performing the same |
WO2020178744A1 (en) * | 2019-03-04 | 2020-09-10 | University Health Network | T cell receptors and methods of use thereof |
CN113785065A (en) * | 2019-03-04 | 2021-12-10 | 大学健康网络 | T cell receptors and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102387813A (en) | 2012-03-21 |
PT2413956T (en) | 2016-12-30 |
JP5756792B2 (en) | 2015-07-29 |
EP2413956A1 (en) | 2012-02-08 |
ES2608715T3 (en) | 2017-04-12 |
HRP20161710T1 (en) | 2017-02-24 |
HUE030195T2 (en) | 2017-04-28 |
PL2413956T3 (en) | 2017-06-30 |
CA2756238A1 (en) | 2010-10-07 |
US8900600B2 (en) | 2014-12-02 |
EP2413956B1 (en) | 2016-09-14 |
BRPI0924827A2 (en) | 2019-01-08 |
JP2012522500A (en) | 2012-09-27 |
DK2413956T3 (en) | 2017-01-09 |
CN102387813B (en) | 2018-07-31 |
US20120082692A1 (en) | 2012-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8900600B2 (en) | Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy | |
CA2764760C (en) | Identification, optimization and use of shared hla-b*0702 epitopes for immunotherapy | |
JP5393144B2 (en) | HLA-A * 3303 restricted WT1 peptide and pharmaceutical composition comprising the same | |
AU2005265182B2 (en) | Epitope analogs | |
AU2006259307B2 (en) | Epitope analogues | |
US20170202936A1 (en) | Identification, Optimization And Use Of Cryptic HLA-B7 Epitopes For Immunotherapy | |
US10149896B2 (en) | MHC-I restricted epitopes containing non-natural amino acid residues | |
JP6255360B2 (en) | Identification, optimization and use of immunotherapy for shared HLA-B * 0702 epitopes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980158591.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09785926 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2756238 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012502822 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7619/CHENP/2011 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2009785926 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009785926 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13258227 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0924827 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0924827 Country of ref document: BR Free format text: COM BASE NA RESOLUCAO 81/2013, SOLICITA-SE A APRESENTACAO DA DECLARACAO DE LISTAGEM DE SEQUENCIAS IMPRESSA E ASSINADA. |
|
ENP | Entry into the national phase |
Ref document number: PI0924827 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110929 |